US 11,692,029 B2
Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
Ji Min, Boston, MA (US); Kin-Sang Cho, Boston, MA (US); and Dong Feng Chen, Newtonville, MA (US)
Assigned to The Schepens Eye Research Institute, Inc., Boston, MA (US)
Appl. No. 16/977,783
Filed by The Schepens Eye Research Institute, Inc., Boston, MA (US)
PCT Filed Mar. 5, 2019, PCT No. PCT/US2019/020787
§ 371(c)(1), (2) Date Sep. 2, 2020,
PCT Pub. No. WO2019/173361, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/638,884, filed on Mar. 5, 2018.
Prior Publication US 2020/0399361 A1, Dec. 24, 2020
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 9/00 (2006.01); A61K 38/19 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/243 (2013.01) [A61K 9/0048 (2013.01); A61K 38/193 (2013.01); C07K 16/2866 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01)] 20 Claims
 
1. A method for treating glaucoma in a subject comprising intravitreally administering to the eye an antagonistic CSF1 receptor antibody.